We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CALQUENCE AstraZeneca Pty Ltd
Product name
CALQUENCE
Sponsor
Accepted date
Jan-2025
Active ingredients
acalabrutinib maleate monohydrate
Proposed indication
CALQUENCE (acalabrutinib) is for the treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma (either as a monotherapy or in combination with other anticancer drugs).
Application type
C (new indication)
Publication date
Jan-2025